Antibody treatments for cancer and other diseases are typically delivered intravenously, because of the large volumes that ...
13h
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China
China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback